Debate On FDA User Fee Reauthorization Begins To Take Shape

A battle may be forming over the 2027 FDA user fee reauthorizations. At a conference Friday, Democratic Rep. Jake Auchincloss supports them for their effectiveness, while Deputy FDA Commissioner Grace Graham echoed criticisms from HHS Sec. Kennedy, among others, in calling for reform to ensure public trust.

Rep. Jake Auchincloss, D-MA, pictured in front of the Capitol building in 2024.
Rep. Jake Auchincloss, D-MA, pictured in front of the Capitol building in 2024. Auchincloss recently spoke in support of user fee programs. (Philip Yabut/Shutterstock)

Trump administration political appointees and Congressional Democrats may be headed for a significant battle over the 2027 user fee reauthorization package, comments made Friday during the Food and Drug Law Institute annual conference in Washington, DC, suggest.

Key Takeaways
  • The 2027 FDA user fee reauthorization process may be shaped by political disagreements.

Many of the US Food and Drug Administration’s current user fee packages will expire in late 2027 and must be...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legislation

More from Policy & Regulation